Evidence map›Paper›PMID 30552619›Full record

ArticleImmunologic research2019

FcRγ deficiency improves survival in experimental sepsis by down-regulating TLR4 signaling pathway.

Zhi-Min Wei, Zhuo Wang, Xiao-Jian Wan, Xian-Jing Li, Yi-Xing Li, Yang Bai, Xue Yang, Yong Yang, Shun-Chang Jiao, Zhe-Feng Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Experimental and therapeutic medicine · 2026
    Review
  2. Article
  3. The Pathogenesis of Sepsis and Potential Therapeutic Targets.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Zhi-Min WeiDepartment of Oncology, General Hospital of Chinese PLA, 28 Fuxing Road, Beijing, 100853, China.
Zhuo WangState Key Laboratory of Natural Medicines, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, 211198, China.
Xiao-Jian WanDepartment of Anesthesiology and Intensive Care Medicine, Changhai Hospital, Second Military Medical University, 800 Xiangyin Rd, Yangpu Qu, Shanghai, China.
Xian-Jing LiState Key Laboratory of Natural Medicines, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, 211198, China.
Yi-Xing LiState Key Laboratory of Natural Medicines, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, 211198, China.
Yang BaiState Key Laboratory of Natural Medicines, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, 211198, China.
Xue YangState Key Laboratory of Natural Medicines, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, 211198, China.
Yong YangState Key Laboratory of Natural Medicines, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, 211198, China. valianty@hotmail.com.
Shun-Chang JiaoDepartment of Oncology, General Hospital of Chinese PLA, 28 Fuxing Road, Beijing, 100853, China. jiaosc@vip.sina.com.
Zhe-Feng LiuDepartment of Oncology, General Hospital of Chinese PLA, 28 Fuxing Road, Beijing, 100853, China. Lzf1220@sina.com.
China Pharmaceutical University · CNChinese PLA General Hospital · CNNanjing University of Chinese Medicine · CNSecond Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fc receptor common γ signaling chain (FcRγ), a common subunit shared by Fc receptors (FcγRI, III, IV, FcαRI, and FcεRI), is an important immune regulator both in innate and adaptive immunity. Previous studies have shown that FcRγ was a potential target of inflammatory diseases, whereas the role of FcRγ in sepsis has been poorly understood. In this study, we found that deficiency of FcRγ resulted in increased survival in lipopolysaccharide (LPS)/D-galactosamine and E. coli-induced sepsis in mice. This protective effect was characterized by decreased TNF-α, IL-6, and IL-10. Further experiments in bone marrow-derived macrophages (BMDMs) in vitro also showed that FcRγ deficiency resulted in decreased production of TNF-α, IL-6, and IL-10 upon LPS stimulation. The mechanism study showed that FcRγ was physiologically associated with toll-like receptor 4 (TLR4), and tyrosine phosphorylation of FcRγ mediated TLR4 signaling pathway, followed by increased ERK phosphorylation upon LPS stimulation. Our results suggest that FcRγ might be a potential therapeutic target of sepsis.

Indexed as

AnimalsCytokinesDisease Models, AnimalDown-RegulationEscherichia coliEscherichia coli InfectionsHumansLipopolysaccharidesMAP Kinase Signaling SystemMiceMice, Inbred C57BLMice, KnockoutReceptors, IgGSepsisToll-Like Receptor 4CytokinesFcgr1 protein, mouseLipopolysaccharidesReceptors, IgGTlr4 protein, mouseToll-Like Receptor 4ERKFcRγLPSTLR4

Identifiers

PMID30552619
OpenAlexW2903944448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.